Research ArticleCORONAVIRUS

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

See allHide authors and affiliations

Science Translational Medicine  02 Sep 2020:
Vol. 12, Issue 559, eabc3103
DOI: 10.1126/scitranslmed.abc3103

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: 1.8-4.7% false positive rate of COVID-19 in antibody testing with a nucleocapsid protein: A potential issue in seroepidemiological surveys?
    • Qiang Zeng, MD, Dean, Health Management Institute, Chinese PLA General Hospital
    • Other Contributors:
      • Yong-zhe Li, MD, Director, Department of Laboratory Medicine, Peking Union Medical College Hospital
      • Yang Xu, MD, Director, Shanghai University of Medicine and Health Sciences
      • Bo Ding, MD, Chinese PLA Hangzhou Sanatorium
      • Biao-yang Lin, PhD, Zhejiang University

    To The Editor:

    Serological testing is a critical investigative tool in the coronavirus disease (COVID-19) epidemic and can identify an infected family or school cluster, especially children or patients with mild or asymptomatic illness. So far, the mortality rate associated with COVID-19 has been calculated based on the incidence of symptomatic patients diagnosed by polymerase chain reaction (PCR).

    Lancet first reported false positive rate of COVID-19 in antibody testing in Spain (1). Pollán and colleagues observed an important national survey that seroprevalence was 5.0% by the point-of-care test and 4.6% by immunoassay, respectively (1). In PCR confirmed COVID-19 cases, the positive rate of serological testing was 45.6-88.6% by the point-of-care test, which is designed to detect antibodies to the spike protein of SARS-CoV-2 and 65.8-90.1% by an Abbott Architect SARS-CoV-2 IgG CMIA test kit (2), which is designed to detect IgG antibodies to the nucleocapsid (N) protein of SARS-CoV-2, suggesting that it has the cross-reactivity of SARS-CoV-2 antibody testing.

    NEJM confirmed false positive rate of COVID-19 in antibody testing. In the study by Gudbjartsson and colleagues, a false positive rate of 1.8% in samples collected in 2017 in Iceland is performed in an assay using an N protein of SARS-CoV-2 as an antigen (3).

    Grzelak and colleagues (4) also found that the false positive rate of COVID-19 in antibody testing with a SARS-CoV-2 N protein is a...

    Show More
    Competing Interests: None declared.
  • RE: False positive results in seroprevalence survey and the second infection of SARS-CoV-2
    • Yang Xv, MD, Chinese Academy of Medical Sciences

    To The Editor:

    As clinicians puzzling to deal with patients with second infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we want to understand why patients would get the second infection of SARS-CoV-2.

    In that vitality, I discovered 4.7% false positive result in antibody testing among persons without SARS-CoV-2 infection in France in this issue of Science Translational Medicine of interest (1). In this study, 23 of 491 samples collected pre-pandemic and without SARS-CoV-2 infection had a positive result in the SARS-CoV-2 antibody testing using a SARS-CoV-2 nucleocapsid (N) protein as an antigen. It is important to understand why some people without SARS-CoV-2 infection produce positive results in the SARS-CoV-2 antibody test.

    Grifoni et al. (2) demonstrated that common cold coronaviruses can exhibit substantial cross-reactivity to the N protein of SARS-CoV-2. If the person shows the N protein cross-reaction and an N antigen is used in the assay, it may cause the false positive result. If a person without symptoms is tested as false positive for COVID-19 in seroprevalence survey but is later infected with SARS-CoV-2, the infection will be erroneously considered as a second SARS-CoV-2 infection.

    Seasonal “common cold” human coronaviruses are continuously circulating among 7-18% of adults with upper respiratory tract infections (3). Answers to these pointed questions might lead to better understand why some patients will...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine

Navigate This Article